Section Arrow
MRSN.NASDAQ
- Mersana Therapeutics
Quotes are at least 15-min delayed:2024/05/18 08:15 EDT
Last
 2.73
+0.15 (+5.81%)
Day High 
2.78 
Prev. Close
2.58 
1-M High
3.83 
Volume 
2.51M 
Bid
2.6
Ask
2.77
Day Low
2.49 
Open
2.6 
1-M Low
2.45 
Market Cap 
315.69M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.94 
20-SMA 3.04 
50-SMA 3.94 
52-W High 9.62 
52-W Low 0.8014 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.12/-1.82
Enterprise Value
343.99M
Balance Sheet
Book Value Per Share
0.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.86M
Operating Revenue Per Share
0.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NBYNovaBay Pharmaceuticals0.1186-0.0014-1.17%-- 
SCPXScorpius Holdings0.1035+0.0034+3.40%-- 
JAGXJaguar Health0.2585-0.0282-9.84%-- 
DNAGinkgo Bioworks Holdings0.8056-0.0334-3.98%-- 
ONCOOnconetix0.156+0.015+10.64%-- 
Quotes are at least 15-min delayed:2024/05/18 08:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.